Skip Navigation

Annals of Oncology 2006 17(11):1611-1613; doi:10.1093/annonc/mdl416
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ma, B.
Right arrow Articles by Chan, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ma, B.
Right arrow Articles by Chan, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

editorial

Transcriptional profiling of tumor biopsies in oncology trials—a ‘window’ of opportunity for evaluating new drugs in nasopharyngeal cancer?

BBY Ma and ATC Chan*

Department of Clinical Oncology, Sir Y. K. Pao Center for Cancer, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR, China

*(E-mail: anthony@clo.cuhk.edu.hk)

The first 150 words of the full text of this article appear below.

Historically, microarray-based expression profiling of tumor tissues has been used to identify molecular signatures that can promote the precise classification and prognostication of human cancers. There is a recent move toward applying this tool in the development of targeted drugs in oncology, where transcriptional profiling of tumor samples are performed for the purpose of elucidating the mechanisms of drug action and identifying biomakers of drug response [1]. In this issue of the Annals of Oncology, Dr Soo et al. [2] report an interesting study on the pharmacodynamic evaluation of celecoxib that focused on whether it could alter global gene expression, microvessel density (MVD) and proliferation index (Ki-67) in nasopharyngeal cancer (NPC). They designed a window study where subjects with untreated NPC were given 14 days of celecoxib before undergoing curative radiotherapy. Endoscopic biopsies of primary tumor were obtained at baseline and on the 14th day . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Toxicol PatholHome page
K. J Randall and J. R. Foster
The Demonstration of Immunohistochemical Biomarkers in Methyl Methacrylate-Embedded Plucked Human Hair Follicles
Toxicol Pathol, December 1, 2007; 35(7): 952 - 957.
[Abstract] [Full Text] [PDF]